# A Study of LAD191 in Adults With Hidradenitis Suppurativa

> **NCT07151937** · PHASE2 · RECRUITING · sponsor: **Almirall, S.A.** · enrollment: 200 (estimated)

## Conditions studied

- Hidradenitis Suppurativa

## Interventions

- **DRUG:** LAD191
- **OTHER:** Placebo
- **DRUG:** Adalimumab

## Key facts

- **NCT ID:** NCT07151937
- **Lead sponsor:** Almirall, S.A.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-11-05
- **Primary completion:** 2027-05-25
- **Final completion:** 2027-11-25
- **Target enrollment:** 200 (ESTIMATED)
- **Last updated:** 2026-05-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07151937

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07151937, "A Study of LAD191 in Adults With Hidradenitis Suppurativa". Retrieved via MORVS 2026-10-14 from https://api.morvs.ai/clinical/NCT07151937. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*